₩132,200.00
-3500.00 (-2.58%)
KRW · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where 090430.KS is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
23 interventional
Held by 0 tracked-famous managers · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Clinical Study to Evaluate the Body Fat Reducing Effects of Heat-Treated Green Tea Extract ComplexNCT06609603Change of body fat by DEXARandomized · Open-label · Treatment | Not applicable | Recruiting | Dietary supplement: HTGT compound, Placebo | Body Fat | 100 | 2025-05-30 | 2024-09-24 |
| Clinical Study to Evaluate the Effects and Safety of Green Tea Extract on Blood Glucose RegulationNCT06592365Change in fasting glucose levelRandomized · Double-masked · Other | Not applicable | Recruiting | Dietary supplement: GTE, Placebo | Blood Sugar | 84 | 2024-12-31 | 2024-09-19 |
| Evaluated the Efficacy and Safety of APCP on Hair HealthNCT06422026Change from baseline in hair tensile strengthRandomized · Quadruple-masked · Other | Not applicable | Completed | Dietary supplement: APCP I, APCP II, Placebo | Hair Damage | 150 | 2024-01-30actual | 2024-05-22 |
| Clinical Study to Evaluate the Body Fat Reducing Effect and Safety of GTB1NCT06422013Changes of percent body fat(trunk, total ect.)Randomized · Quadruple-masked · Other | Not applicable | Completed | Dietary supplement: GTB1, Placebo | Body Fat | 100 | 2023-12-08actual | 2024-05-22 |
| Clinical Trial to Evaluate of Efficacy and Safety of Ginsengberry Concentrate on Fatigue.NCT05725044CISRandomized · Triple-masked · Treatment | Not applicable | Completed | Dietary supplement: Ginsengberry concentrate, Placebo | Fatigue | 88 | 2023-03-03actual | 2023-05-26 |
| Efficacy and Safety of AP Collagen Peptide on the SkinNCT05059197Change from baseline in epidermal hydrationRandomized · Quadruple-masked · Supportive care | Not applicable | Completed | Dietary supplement: AP collagen peptide, Placebo | Dry Skin | 54 | 2021-09-30actual | 2021-11-11 |
| Clinical Study to Evaluate the Blood Triglyceride Decreasing Effect and Safety of Korean Post-Fermented Tea ExtractsNCT04850352Change in fasting triglyceridesRandomized · Double-masked · Other | Not applicable | Completed | Dietary supplement: Heukcha Extracts, Placebo | Triglycerides High | 100 | 2021-03-03actual | 2021-06-16 |
| Clinical Study to Investigate the Sleep Quality Enhancing Effect of GABANCT04857021Change of total sleep time of polysomnographyRandomized · Quadruple-masked · Other | Not applicable | Completed | Dietary supplement: GABA, Placebo | Sleep Disturbance | 60 | 2021-02-15actual | 2021-09-20 |
| Clinical Study to Evaluate the Short Time Efficacy of AP Green Tea Extract Affer High Fat, High Carbohydrate DietNCT04850326Change of Blood glucose levelNon-randomized · Open-label · Supportive care | Not applicable | Completed | Dietary supplement: AP green tea extract | Blood Glucose, High | 20 | 2021-01-02actual | 2021-06-16 |
| Clinical Study to Evaluate the IBS Symptoms Improving Effect and Safety of GTB1NCT05277428Changes in a global relief at 4 weeksRandomized · Double-masked · Other | Not applicable | Completed | Dietary supplement: GTB1, Placebo | Irritable Bowel Syndrome With Diarrhea | 27 | 2020-12-31actual | 2022-05-17 |
| Anti-pollution Effects of AP Green Tea ExtractsNCT04340375Pulmonary function testOpen-label · Other | Not applicable | Completed | Dietary supplement: AP green tea extracts | Respiratory Conditions Due to Unspecified External Agent | 40 | 2020-02-28actual | 2021-06-16 |
| CAPTAIN-AD: Clinical Study of AmorePacific's TRPV1 Antagonist in Atopic DermatitisNCT02965118Success rate of Investigator's Global Assessment (IGA)Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: PAC-14028 cream 1.0%, PAC-14028 cream Vehicle | Atopic Dermatitis | 240 | Nov 2018actual | 2018-11-20 |
| A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Pediatric Atopic DermatitisNCT02748993Success rate of Investigator's Global Assessment (IGA)Randomized · Quadruple-masked · Treatment | Phase 1/2 | Completed | Drug: PAC-14028 Cream 0.1%, PAC-14028 Cream 0.3%, PAC-14028 Cream 1.0%, PAC-14028 Cream Vehicle | Atopic Dermatitis | 56 | Sep 2018actual | 2018-11-20 |
| A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in RosaceaNCT02583009Change in Investigator Global Assessment (IGA)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: PAC-14028 cream 0.1%, PAC-14028 cream 0.3%, PAC-14028 cream 1.0%, PAC-14028 cream vehicle | Rosacea | 216 | Aug 2016actual | 2016-09-20 |
| A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Adults With Atopic DermatitisNCT02757729Success rate of Investigator's Global Assessment (IGA)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: PAC-14028 cream 0.1%, PAC-14028 cream 0.3%, PAC-14028 cream 1.0%, PAC-14028 cream vehicle | Atopic Dermatitis | 192 | Aug 2016actual | 2016-09-20 |
| A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Skin PruritusNCT02565134Change in intensity of pruritus as measured by 10 cm VASRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: PAC-14028 cream 0.1%, PAC-14028 cream 0.3%, PAC-14028 cream 1.0%, PAC-14028 cream vehicle | Skin Pruritus | 296 | Jun 2016actual | 2016-07-15 |
| A Study to Assess the Safety, Tolerability and Pharmacokinetics of PAC-14028 Cream in Healthy Male SubjectsNCT02309008Safety/Tolerability (adverse events, abnormal vital signs, ECG test, clinical lab tests, Numerical pain recording scale)Randomized · Double-masked | Phase 1 | Completed | Drug: PAC-14028 · Other: Vehicle | Healthy | 24 | Apr 2016actual | 2016-04-22 |
| A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Seborrheic DermatitisNCT02749383Treatment success rate in IGE(Investigator's Global Evaluation)Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: PAC-14028 cream 0.3%, PAC-14028 cream 1.0%, PAC-14028 cream vehicle | Seborrheic Dermatitis | 75 | Dec 2014actual | 2016-04-25 |
| A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Atopic DermatitisNCT02583022SCORing Atopic Dermatitis (SCORAD) indexRandomized · Open-label · Treatment | Phase 2 | Completed | Drug: PAC-14028 cream 1.0%, PAC-14028 cream vehicle, Elidel cream 1% | Atopic Dermatitis | 74 | Jan 2014actual | 2015-10-21 |
| Evaluation of the Antipruritic Effect of PAC-14028 Cream in Skin PruritusNCT02052531Change in Visual Analog Scale (VAS)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: PAC-14028 · Other: Vehicle | Skin Pruritus | 74 | Jun 2013actual | 2015-09-14 |
| Study to Evaluate the Efficacy and Safety of PAC-14028 Cream in Rosacea PatientsNCT02052999Change in Investigator Global Assessment (IGA)Randomized · Open-label · Treatment | Phase 2 | Completed | Drug: PAC-14028 cream 1%, Rozex gel 0.75% · Other: Vehicle | Erythematotelangiectatic Rosacea, Papulopustular Rosacea | 80 | Jun 2013actual | 2014-02-03 |
| Cumulative Irritation Test of PAC-14028 in Healthy VolunteersNCT01638117Irritation Score (5-point scale, 0-4)Randomized · Quadruple-masked | Phase 1 | Completed | Other: PAC14028-Vehicle, Saline, Positive · Drug: PAC14028-0.1, PAC14028-0.3, PAC14028-1.0 | Healthy | 35 | Aug 2012actual | 2014-01-22 |
| PAC-14028 in Healthy Male VolunteersNCT01264224Safety/TolerabilityRandomized · Triple-masked | Phase 1 | Completed | Drug: PAC-14028 | Healthy | 60 | Jun 2012actual | 2014-01-22 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19